03 December, 2025 in Investor Relations Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
02 December, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
